Billion-dollar bio-based chemicals IPO window is open, as Solazyme IPOs and Myriant files

Solazyme's much-anticipated initial public offering (IPO) finally happened last Friday, selling about 11 million shares at $18 – raising $198 million in total, twice what it expected when it filed (see the March 29, 2011 LRMCJ). Today the stock is trading up 20% at about $22, for a valuation of $1.3...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Ginkgo Bioworks to go public via $17.5 billion SPAC deal

News Commentary | May 13, 2021

Backed by Harry Sloan and Jeff Sagansky, this merger with Soaring Eagle Acquisition will give Ginkgo a pre‑money equity valuation of $15 billion, with an additional $2.5 billion for the combined entity – one of the biggest SPAC deals in recent times. This news comes on the heels of Zymergen's IPO ... To read more, click here.

Funding momentum for cell-based meat continues as Aleph Farms raises $105 million Series B

News Commentary | July 08, 2021

L Catterton and DisruptAD, the venture capital arm of ADQ, led this Series B round, with participation from other corporate strategic investors like Thai Union Group, Cargill, and CJ CheilJedang, among others. Aleph Farms will use this funding to scale up cell‑based beef steak production and to ... Not part of subscription

LanzaTech goes public in a USD 2.2 billion SPAC deal

News Commentary | March 11, 2022

The climax of LanzaTech's high commercial momentum in the last two years is its announcement to go public by merging with a special purpose acquisition company (SPAC) in a deal that will raise USD 275 million: USD 150 million from the SPAC and USD 125 million from existing investors like BASF, ... Not part of subscription